Multiple Sclerosis Treatment Costs Spike: Patients in Pakistan Seek Government Support

Multiple Sclerosis (MS) patients in Pakistan’s Khyber Pakhtunkhwa province have voiced serious concerns over the escalating costs of neurological treatments. The financial burden of managing this chronic disease has become unsustainable for many, particularly young individuals who are most at risk of developing the condition. Patients are urging the provincial and federal governments to provide dedicated financial support and subsidies for life-altering medications. The lack of access to advanced treatment options in regional hospitals further exacerbates the situation, leaving many without the necessary interventions to manage their symptoms and prevent long-term disability.

In India, the narrative surrounding Multiple Sclerosis has shifted toward awareness and institutional support during recent World MS Day observations. In Hyderabad, healthcare providers and advocates gathered to promote inclusion and better diagnostic facilities for those living with the 'invisible disability.' Marengo Asia Hospitals recently launched a specialized MS clinic to provide targeted care, reflecting a growing infrastructure for neurological health in urban India. A 10-point National Policy Dialogue declaration has also been adopted in India, calling for stronger recognition of MS under national disability frameworks to ensure better legal and financial protections for patients.

The disparity in treatment accessibility between India and Pakistan highlights the urgent need for a unified South Asian approach to chronic neurological care. For patients in Pakistan, the immediate priority is the stabilization of drug prices and the expansion of the government's health insurance coverage to include MS-specific therapies. In India, the focus remains on implementing the landmark policy recommendations to improve the quality of life for women, who are disproportionately affected by the disease. As both nations grapple with the economic impact of chronic illnesses, the integration of MS care into national health agendas will be critical for reducing the long-term socio-economic costs of untreated disabilities.